

# Brian D Lowes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5228827/publications.pdf>

Version: 2024-02-01

104  
papers

6,953  
citations

76326

40  
h-index

58581

82  
g-index

107  
all docs

107  
docs citations

107  
times ranked

7245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	7.4	28
2	TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study. Genetics in Medicine, 2022, 24, 1495-1502.	2.4	5
3	Pulmonary Function Testing Pre-heart Transplant Predicts Posttransplant Survival. Transplantation Direct, 2021, 7, e752.	1.6	1
4	Preoperative Right Heart Dysfunction and Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 324-331.	1.6	8
5	Recurrent pump thrombosis is common after axial continuous-flow left ventricular assist device exchange. International Journal of Artificial Organs, 2020, 43, 109-118.	1.4	5
6	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. American Heart Journal, 2020, 230, 35-43.	2.7	8
7	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. JACC Basic To Translational Science, 2020, 5, 871-883.	4.1	51
8	Transcriptional and free radical responses to LVAD therapy. Translational Medicine Communications, 2020, 5, .	1.4	0
9	Impact of temporary mechanical circulatory support for early graft failure on post-heart transplantation outcomes. Clinical Transplantation, 2020, 34, e14060.	1.6	5
10	Electronic cigarette extract induced toxic effect in iPS-derived cardiomyocytes. BMC Cardiovascular Disorders, 2020, 20, 357.	1.7	8
11	Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]). Circulation, 2020, 142, 2016-2028.	1.6	108
12	Impaired Exercise Tolerance Early After Heart Transplantation Is Associated With Development of Cardiac Allograft Vasculopathy. Transplantation, 2020, 104, 2196-2203.	1.0	2
13	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	3.6	70
14	Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent. JAMA Cardiology, 2020, 5, 411.	6.1	109
15	Percutaneous Deactivation of Left Ventricular Assist Devices. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 467-472.	0.6	9
16	Perioperative Management of Pheochromocytoma Resection in a Patient with a Continuous Flow Left Ventricular Assist Device. Journal of the Saudi Heart Association, 2020, 32, 233-235.	0.4	1
17	Sirolimus for Recurrent Giant Cell Myocarditis After Heart Transplantation: A Unique Therapeutic Strategy. American Journal of Therapeutics, 2019, 26, e600-e603.	0.9	8
18	Left Ventricular Assist Devices in Pulmonary Hypertension Group 2 With Significantly Elevated Pulmonary Vascular Resistance: A Bridge to Cure. Heart Lung and Circulation, 2019, 28, 946-952.	0.4	36

#	ARTICLE	IF	CITATIONS
19	Can we expect improvements in outcomes with centrifugal vs axial flow left ventricular assist devices in patients transitioned from extracorporeal life support?. <i>Journal of Cardiac Surgery</i> , 2019, 34, 1228-1234.	0.7	1
20	TGF- $\beta$ 2 induces a heart failure phenotype via fibroblasts exosome signaling. <i>Heliyon</i> , 2019, 5, e02633.	3.2	15
21	Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. <i>PLoS ONE</i> , 2019, 14, e0221519.	2.5	8
22	Elevated Heart Rate Following Heart Transplantation Is Associated With Increased Graft Vasculopathy and Mortality. <i>Journal of Cardiac Failure</i> , 2019, 25, 249-256.	1.7	7
23	A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. <i>New England Journal of Medicine</i> , 2019, 380, 1618-1627.	27.0	837
24	Do Psychosocial Factors Have Any Impact on Outcomes After Left Ventricular Assist Device Implantation?. <i>ASAIO Journal</i> , 2018, 64, e43-e47.	1.6	25
25	Depression and anxiety in patients undergoing left ventricular assist device implantation. <i>International Journal of Artificial Organs</i> , 2018, 41, 76-83.	1.4	11
26	Risk Factors for In-Hospital Mortality in Heart Failure Patients: Does Rurality, Payer or Admission Source Matter?. <i>Journal of Rural Health</i> , 2018, 34, 103-108.	2.9	5
27	The Effect of Donor Alcohol Abuse on Outcomes Following Heart Transplantation. <i>Clinical Transplantation</i> , 2018, 33, e13461.	1.6	3
28	Sinus tachycardia is associated with impaired exercise tolerance following heart transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12946.	1.6	5
29	Effect of diltiazem on exercise capacity after heart transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12997.	1.6	4
30	Structural and Functional Phenotyping of the Failing Heart. <i>JACC: Heart Failure</i> , 2017, 5, 772-781.	4.1	53
31	Myocardial microRNAs associated with reverse remodeling in human heart failure. <i>JCI Insight</i> , 2017, 2, e89169.	5.0	42
32	Outcomes in Patients with Severe Preexisting Renal Dysfunction After Continuous-Flow Left Ventricular Assist Device Implantation. <i>ASAIO Journal</i> , 2016, 62, 261-267.	1.6	32
33	Targeted myocardial gene expression in failing hearts by RNA sequencing. <i>Journal of Translational Medicine</i> , 2016, 14, 327.	4.4	22
34	Use of the Late-Life Function and Disability Instrument for Measuring Physical Functioning in Patients With Heart Failure. <i>Journal of Nursing Measurement</i> , 2016, 24, 323-336.	0.3	2
35	Inhaled Milrinone After Left Ventricular Assist Device Implantation. <i>Journal of Cardiac Failure</i> , 2015, 21, 792-797.	1.7	34
36	Therapeutic Molecular Phenotype of $\beta$ -Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 270-283.	5.1	40

#	ARTICLE	IF	CITATIONS
37	Timed Response to Inhaled Nitric Oxide in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 103-109.	1.7	3
38	Risk of Death in Heart Disease is Associated With Elevated Urinary Globotriaosylceramide. <i>Journal of the American Heart Association</i> , 2014, 3, e000394.	3.7	22
39	Combined Heart and Liver Transplantation Against Positive Cross-Match for Patient With Hypoplastic Left Heart Syndrome. <i>Transplantation</i> , 2014, 98, e100-e102.	1.0	10
40	Cytomegalovirus reactivation and colitis after left ventricular assist device placement. <i>International Journal of Infectious Diseases</i> , 2013, 17, e348-e351.	3.3	8
41	Worsening Renal Function in Patients With Acute Decompensated Heart Failure Treated With Ultrafiltration: Predictors and Outcomes. <i>Journal of Cardiac Failure</i> , 2013, 19, 787-794.	1.7	8
42	Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. <i>Cardiovascular Research</i> , 2013, 97, 66-76.	3.8	41
43	Left Ventricular Assist Device Effects on Metabolic Substrates in the Failing Heart. <i>PLoS ONE</i> , 2013, 8, e60292.	2.5	19
44	Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. <i>Nature Medicine</i> , 2012, 18, 774-782.	30.7	278
45	A Personalized BEST: Characterization of Latent Clinical Classes of Nonischemic Heart Failure That Predict Outcomes and Response to Bucindolol. <i>PLoS ONE</i> , 2012, 7, e48184.	2.5	21
46	Incomplete Recovery of Myocyte Contractile Function Despite Improvement of Myocardial Architecture With Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2011, 4, 425-432.	3.9	69
47	Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. <i>Clinical and Translational Science</i> , 2010, 3, 249-253.	3.1	33
48	An $\hat{1}\pm$ 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the $\hat{1}^2$ -Blocker Bucindolol in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 21-28.	3.9	103
49	Overdrive Pacing Suppresses Ectopy and Minimizes Left Ventricular Assist Device Suction Events. <i>Circulation: Heart Failure</i> , 2009, 2, 516-517.	3.9	3
50	Myocardial glucose and lactate metabolism during rest and atrial pacing in humans. <i>Journal of Physiology</i> , 2009, 587, 2087-2099.	2.9	66
51	Myocardial FFA metabolism during rest and atrial pacing in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E358-E366.	3.5	14
52	Genetic determinants of drug response in heart failure. <i>Current Cardiology Reports</i> , 2008, 10, 176-181.	2.9	6
53	Genetic determinants of drug response in heart failure. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 485-490.	2.0	0
54	Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 774-777.	0.8	44

#	ARTICLE	IF	CITATIONS
55	Impact of Cardiac Resynchronization Therapy on Exercise Performance, Functional Capacity, and Quality of Life in Systolic Heart Failure With QRS Prolongation: COMPANION Trial Sub-Study. <i>Journal of Cardiac Failure</i> , 2008, 14, 9-18.	1.7	82
56	Myocardial protection in sepsis. <i>Critical Care</i> , 2008, 12, 177.	5.8	1
57	Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 922-925.	1.5	53
58	Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: Results of the oral enoximone in intravenous inotrope-dependent subjects trial. <i>American Heart Journal</i> , 2007, 154, 861-869.	2.7	25
59	Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST). <i>Journal of Cardiac Failure</i> , 2007, 13, 437-444.	1.7	17
60	Assist Devices Fail to Reverse Patterns of Fetal Gene Expression Despite $\beta$ -Blockers. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1170-1176.	0.6	18
61	Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST). <i>Journal of Cardiac Failure</i> , 2007, 13, 732-737.	1.7	40
62	Serial Gene Expression Profiling in the Intact Human Heart. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 579-588.	0.6	28
63	Gene expression profile of the recovering human heart. <i>European Heart Journal</i> , 2006, 28, 522-524.	2.2	6
64	BOOP is Common in Cardiac Transplant Recipients Switched from a Calcineurin Inhibitor to Sirolimus. <i>American Journal of Transplantation</i> , 2005, 5, 1392-1396.	4.7	37
65	Molecular remodeling in the failing human heart. <i>Current Heart Failure Reports</i> , 2005, 2, 5-9.	3.3	6
66	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2005, 111, 113-117.	1.6	111
67	Rationale and Design of the Enoximone Clinical Trials Program. <i>Journal of Cardiac Failure</i> , 2005, 11, 659-669.	1.7	26
68	Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1064-1071.	2.8	167
69	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2004, 110, 3858-3865.	1.6	200
70	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2004, 110, 3734-3740.	1.6	153
71	Peak oxygen consumption and outcome in heart failure patients chronically treated with $\beta$ -blockers. <i>Journal of Cardiac Failure</i> , 2004, 10, 15-20.	1.7	31
72	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. <i>Journal of the American College of Cardiology</i> , 2003, 42, 914-922.	2.8	198

#	ARTICLE	IF	CITATIONS
73	Hormone replacement therapy is associated with improved survival in women with advanced heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1238-1245.	2.8	54
74	Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 27-30.	1.7	56
75	Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents. <i>New England Journal of Medicine</i> , 2002, 346, 1357-1365.	27.0	462
76	Altered Expression of Endothelin Receptors in Failing Human Left Ventricles. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 833-846.	1.9	33
77	Inotropes and $\beta$ -blockers: Is there a need for new guidelines?. <i>Journal of Cardiac Failure</i> , 2001, 7, 8-12.	1.7	57
78	Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1950-1956.	2.8	29
79	Predicting response to carvedilol for the treatment of heart failure: A multivariate retrospective analysis. <i>Journal of Cardiac Failure</i> , 2001, 7, 4-12.	1.7	27
80	Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. <i>International Journal of Cardiology</i> , 2001, 81, 141-149.	1.7	128
81	Signaling Pathways Responsible for Fetal Gene Induction in the Failing Human Heart. <i>Circulation</i> , 2001, 103, 1089-1094.	1.6	122
82	Low-dose enoximone improves exercise capacity in chronic heart failure—A list of the Enoximone Study Group Members and institutional affiliations is provided in the appendix.. <i>Journal of the American College of Cardiology</i> , 2000, 36, 501-508.	2.8	58
83	[beta ]-Blockade in adriamycin-induced cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2000, 6, 115-119.	1.7	51
84	Hypotension with Dobutamine: $\beta$ -Adrenergic Antagonist Selectivity at Low Doses of Carvedilol. <i>Annals of Pharmacotherapy</i> , 1999, 33, 1266-1269.	1.9	13
85	Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. <i>American Journal of Cardiology</i> , 1999, 83, 1201-1205.	1.6	275
86	Prevalence of depression in congestive heart failure. <i>American Journal of Cardiology</i> , 1999, 84, 348-350.	1.6	181
87	Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. <i>Journal of Cardiac Failure</i> , 1999, 5, 46-54.	1.7	10
88	Patient preferences for heart failure treatment: Utilities are valid measures of health-related quality of life in heart failure. <i>Journal of Cardiac Failure</i> , 1999, 5, 85-91.	1.7	53
89	The role of third-generation beta-blocking agents in chronic heart failure. <i>Clinical Cardiology</i> , 1998, 21, I3-I13.	1.8	85
90	Combined Oral Positive Inotropic and Beta-Blocker Therapy for Treatment of Refractory Class IV Heart Failure. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1336-1340.	2.8	126

#	ARTICLE	IF	CITATIONS
91	Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol. <i>Journal of Cardiac Failure</i> , 1998, 4, 36.	1.7	16
92	Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. <i>Journal of Cardiac Failure</i> , 1998, 4, 37-44.	1.7	233
93	The Pressure-Overloaded Right Ventricle in Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 101S-106S.	0.8	120
94	Second- and third-generation beta-blocking drugs in chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1997, 11, 291-296.	2.6	30
95	Dilated Cardiomyopathy Associated With Deficiency of the Cytoskeletal Protein Metavinculin. <i>Circulation</i> , 1997, 95, 17-20.	1.6	140
96	Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.. <i>Journal of Clinical Investigation</i> , 1997, 100, 2315-2324.	8.2	455
97	Importance of Angiotensin-Converting Enzyme in Pulmonary Hypertension. <i>Cardiology</i> , 1995, 86, 9-15.	1.4	45
98	Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.. <i>Journal of Clinical Investigation</i> , 1995, 96, 1490-1498.	8.2	101
99	Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. <i>Journal of Cardiac Failure</i> , 1994, 1, 57-62.	1.7	7
100	Low-dose inotropic therapy for ambulatory heart failure. <i>Coronary Artery Disease</i> , 1994, 5, 112-118.	0.7	16
101	Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. <i>Lancet</i> , The, 1993, 342, 1073-1075.	13.7	411
102	Damaging Cardiac and Cancer Genetic Variants in the LVAD Population. <i>The VAD Journal: the Journal of Mechanical Assisted Circulation and Heart Failure</i> , 0, , .	2.0	1
103	Electrocardiographic characteristics, antiarrhythmic utilization, and outcomes in patients with left ventricular assist devices. <i>The VAD Journal: the Journal of Mechanical Assisted Circulation and Heart Failure</i> , 0, , .	2.0	1
104	Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1